PLUR
Pluri Inc.
NASDAQ · Healthcare · Biotechnology · IL
$1.34
−2.03%Year over year
Reported trailing growth
- Revenue
- +4.4%
- EBITDA
- -28.7%
- EBIT
- -20.6%
- EPS
- +25.5%
- Free cash flow
- -19.1%
- Operating cash flow
- -17.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +78.7%
- EBITDA
- -9.1%
- EBIT
- -0.1%
- Net income
- -8.1%
- EPS
- +10.8%
- Free cash flow
- -8.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026